Protalix BioTherapeutics (PLX) Non-Current Deffered Revenue (2010 - 2022)
Protalix BioTherapeutics (PLX) posted quarterly Non-Current Deffered Revenue of $5.9 million for Q2 2022, up 364.54% year-over-year from $1.3 million in Q2 2021, and little changed quarter-over-quarter from $5.9 million in Q1 2022.
Protalix BioTherapeutics (PLX) Non-Current Deffered Revenue (2010 - 2022) Analysis & Trends
Protalix BioTherapeutics' Non-Current Deffered Revenue history runs 13 years deep, the most recent figure standing at $5.9 million for Q2 2022.
- In Q2 2022, Non-Current Deffered Revenue rose 364.54% year-over-year to $5.9 million; the TTM figure through Jun 2022 stood at $5.9 million (up 364.54% YoY), while the FY2021 annual figure was $11.8 million, up 587.06% from the prior year.
- Non-Current Deffered Revenue for Q2 2022 stood at $5.9 million, roughly flat from $5.9 million in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $34.9 million in Q2 2019, with the low at $858000.0 in Q1 2021.
- The 5-year median for Non-Current Deffered Revenue is $9.5 million (2020), against an average of $15.0 million.
- The sharpest annual moves came in 2020 and 2021: Non-Current Deffered Revenue plunged 94.64% in 2020, then jumped 587.06% in 2021.
- Protalix BioTherapeutics' Non-Current Deffered Revenue stood at $33.0 million in 2018, then plunged by 48.59% to $17.0 million in 2019, then sank by 89.89% to $1.7 million in 2020, then surged by 587.06% to $11.8 million in 2021, then slumped by 50.0% to $5.9 million in 2022.
- Business Quant data shows PLX's Non-Current Deffered Revenue at $5.9 million in Q2 2022, $5.9 million in Q1 2022, and $11.8 million in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 147.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Protalix BioTherapeutics | 189.97 Mn | 149.31 Mn | 12.13 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 5.90 Mn |
| Mar 31, 2022 | 5.90 Mn |
| Dec 31, 2021 | 11.79 Mn |
| Sep 30, 2021 | 5.90 Mn |
| Jun 30, 2021 | 1.27 Mn |
| Mar 31, 2021 | 858,000.00 |
| Dec 31, 2020 | 1.72 Mn |
| Sep 30, 2020 | 1.53 Mn |
| Jun 30, 2020 | 4.12 Mn |
| Mar 31, 2020 | 7.13 Mn |
| Dec 31, 2019 | 16.98 Mn |
| Sep 30, 2019 | 28.59 Mn |
| Jun 30, 2019 | 34.91 Mn |
| Mar 31, 2019 | 32.98 Mn |
| Dec 31, 2018 | 33.03 Mn |
| Sep 30, 2018 | 33.49 Mn |
| Jun 30, 2018 | 21.64 Mn |
| Mar 31, 2018 | 22.38 Mn |
| Dec 31, 2017 | 25.02 Mn |
| Sep 30, 2016 | 453,000.00 |